JP2007538044A - ワクチン - Google Patents

ワクチン Download PDF

Info

Publication number
JP2007538044A
JP2007538044A JP2007517101A JP2007517101A JP2007538044A JP 2007538044 A JP2007538044 A JP 2007538044A JP 2007517101 A JP2007517101 A JP 2007517101A JP 2007517101 A JP2007517101 A JP 2007517101A JP 2007538044 A JP2007538044 A JP 2007538044A
Authority
JP
Japan
Prior art keywords
ova
antigen
stxb
adjuvant
vaccine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007517101A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007538044A5 (https=
Inventor
コメツ，パトリック
コリニョン，キャサリン，パスカリーヌ，アン，ギスレーヌ
メッヘレン，マルセル，ポーレット ヴァン
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2007538044A publication Critical patent/JP2007538044A/ja
Publication of JP2007538044A5 publication Critical patent/JP2007538044A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2007517101A 2004-05-21 2005-05-19 ワクチン Pending JP2007538044A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0411411.2A GB0411411D0 (en) 2004-05-21 2004-05-21 Vaccines
PCT/EP2005/005555 WO2005112991A2 (en) 2004-05-21 2005-05-19 Vaccines

Publications (2)

Publication Number Publication Date
JP2007538044A true JP2007538044A (ja) 2007-12-27
JP2007538044A5 JP2007538044A5 (https=) 2008-04-17

Family

ID=32607764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007517101A Pending JP2007538044A (ja) 2004-05-21 2005-05-19 ワクチン

Country Status (16)

Country Link
US (1) US20080069832A1 (https=)
EP (1) EP1761275A2 (https=)
JP (1) JP2007538044A (https=)
KR (1) KR20070029730A (https=)
CN (1) CN1956729A (https=)
AU (1) AU2005244615A1 (https=)
BR (1) BRPI0511185A (https=)
CA (1) CA2564778A1 (https=)
GB (1) GB0411411D0 (https=)
IL (1) IL178890A0 (https=)
MA (1) MA28609B1 (https=)
MX (1) MXPA06013386A (https=)
NO (1) NO20065304L (https=)
RU (1) RU2006139424A (https=)
WO (1) WO2005112991A2 (https=)
ZA (1) ZA200609500B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012523379A (ja) * 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
JP2014505473A (ja) * 2011-01-14 2014-03-06 中国人民解放軍軍事医学科学院附属医院 Ｂ７−１−ｐｅ４０ｋｄｅｌ外毒素融合遺伝子に基づくｄｎａワクチンおよびその使用
JP2014132030A (ja) * 2014-04-08 2014-07-17 Univ Of Melbourne:The 免疫原性組成物およびその使用
JP2014529338A (ja) * 2011-07-22 2014-11-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｐｒａｍｅの精製

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006104890A2 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
JP2008540625A (ja) * 2005-05-19 2008-11-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｅ．ｃｏｌｉ易熱性毒素のＢ−サブユニット、抗原およびアジュバントを含むワクチン組成物
GB0524409D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
GB0524408D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
JP2009536653A (ja) * 2006-05-09 2009-10-15 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド Ｈｉｖ−１免疫原性組成物
EP1938836A1 (en) * 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells
JP5331105B2 (ja) 2007-05-24 2013-10-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 凍結乾燥抗原組成物
GB0724357D0 (en) * 2007-12-14 2008-01-23 Glaxosmithkline Biolog Sa Method for preparing protein conjugates
WO2009126819A1 (en) * 2008-04-09 2009-10-15 Advanced Immune Therapeutics, Inc. Methods for improving the bioactivity of therapeutic ige antibodies for the treatment of disease
AU2009344150B2 (en) * 2009-04-09 2014-10-09 Innavac Pty Ltd Immunogenic composition and uses thereof
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
TW201103980A (en) 2009-07-08 2011-02-01 Abbott Biologicals Bv Viral vaccine and use thereof
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CN104688687A (zh) 2009-12-03 2015-06-10 诺华股份有限公司 疫苗佐剂制备中的亲水过滤
CL2012001399A1 (es) * 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
DE102009056883B4 (de) * 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2506834B1 (en) * 2009-12-03 2016-03-02 Novartis AG Circulation of components during homogenization and microfluidization of emulsions
EP2618842B1 (en) 2010-09-22 2019-04-24 Ena Therapeutics Pty Ltd Novel immunostimulatory method
CN106822883A (zh) 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
US10695424B2 (en) 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
KR101966346B1 (ko) * 2017-01-13 2019-04-05 전북대학교 산학협력단 시가 독소 Stx2e를 제조하는 방법 및 이를 포함하는 부종병을 예방하기 위한 백신 조성물
KR101987851B1 (ko) 2017-04-28 2019-06-11 한국생명공학연구원 장출혈성대장균 유래의 시가독소 타입 1 B-subunit으로 유도된 노인성 황반변성(AMD) 동물모델 및 이를 이용한 스크리닝 방법
BR112019025104A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Método de fabricar um sistema de entrega não viral, sistema de entrega não viral, e, composição
AU2018391325B2 (en) 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
CN108992667A (zh) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 一种带状疱疹疫苗及其制备方法、应用
EP3886901A1 (en) * 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
EP3669890A1 (en) 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
MX2021015961A (es) 2019-06-26 2022-03-22 Ena Respiratory Pty Ltd Moleculas novedosas.
EP4021407A1 (en) 2019-08-30 2022-07-06 GlaxoSmithKline Biologicals S.A. Jet mixing lipid nanoparticle manufacturing process
CN111333734B (zh) * 2020-03-31 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种百日咳丝状血凝素融合蛋白及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07508512A (ja) * 1992-06-25 1995-09-21 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
JP2002504106A (ja) * 1997-06-11 2002-02-05 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム オイル・イン・ウォーターワクチン組成物
JP2002542203A (ja) * 1999-04-19 2002-12-10 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2218601A1 (en) * 1995-03-24 1996-10-03 Ophidian Pharmaceuticals, Inc. Treatment for verotoxin-producing escherichia coli
EP1078007B1 (en) * 1998-05-15 2005-11-23 Institut Curie Verotoxin b subunit for immunization
EP1229045A1 (en) * 2001-02-01 2002-08-07 Institut Curie Universal carrier for targeting molecules to Gb3 receptor expressing cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07508512A (ja) * 1992-06-25 1995-09-21 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
JP2002504106A (ja) * 1997-06-11 2002-02-05 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム オイル・イン・ウォーターワクチン組成物
JP2002542203A (ja) * 1999-04-19 2002-12-10 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012523379A (ja) * 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
JP2014505473A (ja) * 2011-01-14 2014-03-06 中国人民解放軍軍事医学科学院附属医院 Ｂ７−１−ｐｅ４０ｋｄｅｌ外毒素融合遺伝子に基づくｄｎａワクチンおよびその使用
JP2017018122A (ja) * 2011-01-14 2017-01-26 中国人民解放軍軍事医学科学院附属医院Ａｆｆｉｌｉａｔｅｄ Ｈｏｓｐｉｔａｌ Ｏｆ Ａｃａｄｅｍｙ Ｏｆ Ｍｉｌｉｔａｒｙ Ｍｅｄｉｃａｌ Ｓｃｉｅｎｃｅｓ， Ｐｌａ Ｂ７−１−ｐｅ４０ｋｄｅｌ外毒素融合遺伝子に基づくｄｎａワクチンおよびその使用
JP2014529338A (ja) * 2011-07-22 2014-11-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｐｒａｍｅの精製
JP2014132030A (ja) * 2014-04-08 2014-07-17 Univ Of Melbourne:The 免疫原性組成物およびその使用

Also Published As

Publication number Publication date
CN1956729A (zh) 2007-05-02
MXPA06013386A (es) 2007-01-23
IL178890A0 (en) 2007-03-08
AU2005244615A1 (en) 2005-12-01
RU2006139424A (ru) 2008-06-27
MA28609B1 (fr) 2007-05-02
KR20070029730A (ko) 2007-03-14
ZA200609500B (en) 2008-02-27
WO2005112991A2 (en) 2005-12-01
US20080069832A1 (en) 2008-03-20
EP1761275A2 (en) 2007-03-14
BRPI0511185A (pt) 2007-12-04
WO2005112991A3 (en) 2006-03-30
GB0411411D0 (en) 2004-06-23
NO20065304L (no) 2006-11-20
CA2564778A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
JP2007538044A (ja) ワクチン
JP4897547B2 (ja) ワクチン
EP2125012B1 (en) Compositions comprising a b subunit of shiga toxin and a means stimulating nkt cells
JP5307859B2 (ja) ワクチン
US20090035330A1 (en) Vaccine Composition Comprising B-Subunit Of E. coli Heat Toxin And An Antigen And An Adjuvant
CN102026657A (zh) 疟疾疫苗
JP2009517421A (ja) ワクチン
JP2009517422A (ja) 非生抗原性ベクターを含むワクチン
WO2009077438A1 (en) Method for preparing protein conjugates
WO2009077436A2 (en) Method for preparing protein conjugates
CN101180075A (zh) 疫苗
MXPA01010654A (en) Vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110809

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110809